Global landscape of CAR cell therapeutic companies

by Alexey Bersenev on February 2, 2018 · 0 comments

in market

Using recently released Cellular Immunotherapy Companies dataset, I attempted to quantify all therapeutic CAR cell companies worldwide. The dataset includes companies with therapeutic assets/ programs in different stages of development, but not manufacturers of reagents/ devices or service providers.

I was able to identify 115 of CAR cell therapeutic companies. It is ~53% of all immunocellular therapy companies. The vast majority of companies are startups with wholly owned CAR cell assets/ programs. At least 14 large BioPharma companies currently have CAR cell programs/ assets, obtained via licensing and/ or acquisitions (e.g. Pfizer, Amgen, Shire, Regeneron, Johnson & Johnson, ONO Pharmaceuticals, Takeda…). 17 companies (15%), besides CAR cell programs, have other immunocellular product-candidates in development (e.g. NK cells, TCR-T, DC…). About 1/3 of all CAR cell therapeutic companies are in a very early phase of development (preclinical) and 2/3 are conducting clinical trials. Only 2 companies have approved CAR cell products on a market.

Here is a global geographical distribution of CAR cell therapeutic companies (click to enlarge):

CAR tx companies global

Overall, 15 countries have CAR cell companies with a therapeutic focus. China takes 42% of global share of all companies, US – 33%.

Almost all of these companies appeared in the last 5 years (since 2012). Despite some trends for consolidation through acquisition by larger companies (e.g. Gilead –> Kite Pharma, Celgene –> Juno Therapeutics), a number of CAR cell stratups continues to explode. I wanted to illustrate here that CAR cell industry explosion is becoming global and it is spreading rapidly.


Immunocellular therapy companies worldwide

by Alexey Bersenev on January 31, 2018 · 0 comments

in market

I’d love to announce a new dataset, created as part of the Cell Trials Data project – Cellular Immunotherapy Companies. This is the first dataset, where we tried to capture all known industry immune cell therapy developers.

The dataset includes worldwide companies developing only immunotherapeutic cellular products. We captured both – companies with wholly owned products/ programs (mostly startups) and that have assets/ programs via licensing or partnership (mostly large BioPharma) with therapeutic products. All vendors to the Immunotherapy industry, such as manufacturers of reagents and devices or service providers, were excluded from the dataset.

We searched publicly available sources to compile this dataset – clinical trial registries, news, companies press releases, conference materials. For the first time, we created a separate dataset for China.

A total number of companies in the dataset is 215. We identified 68 companies (1/3 of all immunocellular companies worldwide) only in China.

Here is an example how you can use this database:

immunecell companies #

If you’re doing market research in immuno-oncology or immunocellular therapy, this dataset could be a great tool!


Choice of the right target is a key to successful development of CAR cell therapy. Until now the major success of CAR-T cell therapy was related to just one target – CD19. But what about other targets? Is anything else promising in the pipeline? What targets are the most popular for liquid and solid malignancies? How is interest to different CAR cell targets changing over the years? I was trying to answer these questions using All CAR-T Trials database. Analysis cutoff date is October 1, 2017. Here I’m sharing some data.

Total number of targets
I was able to identify 51 targets, mentioned in database listings – 19 targets in liquid malignancies and 32 targets in solid malignancies. Some trials (from China) are describing multiple targets, for example NCT03291444 (CD19, CD20, CD22, CD10, CD33, CD38 CD56, CD117, CD123, CD34) or NCT03267173 (mesothelin, PSCA, CEA, HER2, MUC1, EGFRvIII). Some trials are covering 2 targets as “and/or/bispecific”, for example EUCTR2016-004680-39 (CD19/CD22 bispecific) or NCT03207178 (CD19 and CD20 sequential). Overall, 91% of trials have a single target and 9% of trials have 2 or more targets.

Value of CD19
50% of all registered CAR cell trials are targeting CD19. A small fraction of it is CD19 with other targets (and/or/bispecific):
CD19 share

Targets in liquid malignancies
What is the next most popular target after CD19? Look like CD22, BCMA and CD20 are leading, but bear in mind that most of the trials, involved CD20 and CD22 are done in conjunction with CD19 (and/or/bispecific) – click picture to enlarge:
liquid targets # trials

Targets in solid malignancies
Mesothelin captured the most attention of CAR cell therapy developers in solid malignancies. But it tightly followed by GPC3, GD2, EGFR and CEA – click picture to enlarge:
solid targets # trials

It is important to look at how interest to CAR targets was changing with time. Here is one example of the trend:
CD30 vs BCMA

As you can see from this graph, the interest to CD30 spiked last year, but now is trending down. BCMA took off in 2015 and now is trending up high. The reason – great clinical results.

You can look at any other target and draw the trend line to understand where the field is moving. Get all raw CAR cell trials data and play with it!

{ 1 comment }

Analysis of published results of CAR-T cell therapy trials

September 28, 2017

Recently, Cell Trials Data started to track results of clinical trials from publications. Unlike news, social media, press releases and conference abstracts, published data allow in-depth analysis of trial settings and outcomes. For example, you can learn whether a death case was really cell product related or why dropout rate between enrollment and cell infusion […]

Read the full article →

Historic moment for Chinese CAR-T biotech

June 6, 2017

The biggest and the most prestigious conference in clinical oncology (ASCO) could be a turning point for Chinese CAR-T biotech. Yesterday, presentation of preliminary data from CAR-T trial in multiple myeloma by China’s company Nanjing Legend Biotech (Legend), was a bomb! Repercussions of this success could be historic for perception of Chinese CAR-T biotech by […]

Read the full article →

Analysis of published results of clinical trials in regenerative medicine

May 6, 2017

About two years ago I attempted to analyze published results of regenerative medicine clinical studies. It was very hard and time consuming thing to do, so I’ve ditched my efforts. Recently, I was very happy to find a study by Tania Bubela’s group from University of Alberta, published in Stem Cell Reports. This is the […]

Read the full article →

Historical analysis of cell-based therapeutic products marketed and approved worldwide

April 7, 2017

2017 marks 20 years since the first regulatory approval of cell-based therapeutic product on a market. In 1997 Carticel (manufactured by Genzyme Corp.) was approved by FDA for US market. One year before Carticel approval, 2 cell-based products were launched and marketed for the first time in Europe (Italy) – Laserskin and Hyalograft by Fidia […]

Read the full article →

CAR cell therapy trials in China

February 13, 2017

Many of you know that China is very active in CAR cell therapy field. However, it is not easy to track this activity. I made an attempt to analyze CAR cell trials data from China, using All CAR-T Trials dataset from Cell Trials Data. Here are some of my findings. Until 2010, all CAR cell […]

Read the full article →

Number of CAR cell therapy trials worldwide

February 10, 2017

CAR (Chimeric Antigen Receptor)-based cell clinical trials is one of the hottest areas in cell therapy right now. Today, I’d like to share with you a trend for total number of CAR cell trials, registered worldwide. Importantly, I made figures available for free download on FigShare. You can get it in high resolution and use […]

Read the full article →

Cell therapy trials data

January 25, 2017

Dear readers, as you know I have been collecting cell therapy clinical trials data for several years now. I posted some snapshots, based on my own raw data analysis as “annual reports“. However, I have not shared or offered raw data before. I’m happy to tell you that now everyone can get raw data and […]

Read the full article →